Amgen, Inc.
http://www.amgen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
Novartis, Takeda See Industry Better Prepared For Next Pandemic
Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abgenix
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- Avidia
- BioVex Group
- Catherex, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Ilypsa
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC
- Tularik
- Dezima Pharma